NCT06385509进行中（未招募）4 期
A Phase 4, Open-Label Study to Evaluate Primary Adrenal Function (Glucocorticoid Axis) in Hypogonadal Men Treated With JATENZO® for 12 Months
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- Tolmar Inc.
- 入组人数
- 110
- 试验地点
- 24
- 主要终点
- CST Test
研究概览
简要总结
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
详细描述
Following all screening activities and confirmation that the subject has met all eligibility requirements, JATENZO treatment for approximately 1 year will begin. The dose of JATENZO will be titrated using its standard dose-titration algorithms based on serum testosterone levels. The Treatment Period will consist of Visits 1 - 12, with cosyntropin stimulation test completed at Visit 9 (Day 169 ±7) and Visit 12 (Day 365 ±7). At each visit during the Treatment Period, subjects will be evaluated for signs and symptoms of adrenal insufficiency, occurrence of adverse events, and changes in concomitant medications. There will be a safety follow-up visit 2 weeks after completion of Visit 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject must be a man 18 to 65 years of age, inclusive, with a previous clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism and a low T level as defined by established criteria at the time of diagnosis); subjects must also have at least 1 T level < 300 ng/dL at either Screen 1 or Screen
- •Subject must be naïve to androgen replacement therapy or washed out of prior androgen replacement therapies (wash out durations specified in exclusion criterion); that is, be willing to cease current T treatment, or currently not be taking T treatment.
- •Subject agrees as part of signed informed consent to remain off all forms of T, except for dispensed study drug, throughout the entire study.
- •Subject must have adequate venous access in the left or right arm to allow collection of blood samples.
- •Subject must be able and willing to provide written informed consent and comply with the trial protocol and procedures.
排除标准
- •Subject will be excluded if 1 or more of the main exclusion is applicable:
- •Subject with a history of panhypopituitarism or multiple endocrine deficiencies (whether or not on stable doses of thyroid hormone and adrenal replacement hormones).
- •Subject with a current or prior history of AI.
- •Subject is currently receiving corticosteroids.
- •On the CST at Screen 3, the maximum serum total cortisol at both the 30- and 60-minute timepoint is ≤ 14 mcg/dL or has a baseline CBG outside the reference range.
- •Subject with a history of a short course (2 weeks or less) of any glucocorticoids within the past 3 months or anabolic steroids other than testosterone within the past 6 months.
- •Subject with a history of a protracted course of any glucocorticoid therapy (e.g., inhaled nasal steroids, inhaled oral steroids, topical steroids, injectable steroids such as joint injections) or anabolic steroids other than T. Enrolled subjects who take glucocorticoids while on study drug may be discontinued from the study at the discretion of the investigator in consultation with the sponsor.
- •Subject with a history of anabolic steroid abuse.
- •Subject with a diagnosis of hypogonadism who has received any topical (e.g., gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (e.g., T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (e.g., AVEED®) within the previous 20 weeks, T implantable pellets (Testopel®) product within the previous 6 months or any prior use of an oral testosterone product.
- •Subject has received any drug as part of another research study within 30 days of initial dose administration in this study.
- •Subject has significant intercurrent disease (e.g., liver, kidney, inflammatory bowel disease, uncontrolled or poorly controlled heart disease, including hypertension, thromboembolism, congestive heart failure, or coronary heart disease, psychiatric illness, including severe depression), which in the opinion of the Investigator, would affect study participation or interpretation of study assessments.
- •Subject has untreated, severe obstructive sleep apnea.
- •Subject has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN (except subjects with Gilbert syndrome) and serum creatinine > 1.5 × ULN.
- •Subject has a HCT value of < 35% or > 50%.
- •Subject has a history of polycythemia, either idiopathic or associated with TRT treatment.
- •Subject is diabetic with a glycosylated hemoglobin > 8.5%.
- •Subject has a body mass index (BMI) ≥ 38 kg/m
- •Subject has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.
- •Subject has a mean (triplicate assessments) systolic blood pressure (sBP) > 140 mm Hg and/or diastolic blood pressure (dBP) > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water).
- •Subject has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
- •Subject does not meet the requirements for concomitant medication as outlined below:
- •If hypertensive, on a stable dose of antihypertensive medication for < 3 months
- •If diabetic, on a stable dose of oral medication for < 2 months
- •If on anticonvulsant therapy, on a stable dose for < 3 months
- •If on lipid lowering medications, on a stable dose for < 3 months. Subject is expected to remain on a stable dose of lipid-lowering medication(s) throughout the study.
- •Subject has an abnormal prostate DRE (palpable nodules), elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening.
- •Subject has a history of, or current or suspected prostate cancer.
- •Subject has a history of, or current or suspected breast cancer.
- •Subject currently using a drug known to affect T levels, T metabolism or levels of T metabolites. These include: 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride), estrogens, long-acting opioid analgesics (e.g., methadone hydrochloride, buprenorphine hydrochloride), human growth hormone (HGH) or over-the-counter supplements purported to "boost" testosterone, sexual function or improve prostate symptoms.
- •Subject use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.
- •Subject use of any over-the-counter "adrenal supplements".
- •Subject is not willing to stop all supplemental biotin 3 days prior to testing at intervals described in this protocol.
- •Subject currently using Megace, atypical anti-psychotics (e.g., clozapine, aripiorazole, asenapine, lumateperone, olanzapine, paliperidone, aripiprazole, ziprasidone, cariprazine, risperidone, pimavanserin, ioperidone, brexpiprazole, lurasidone, quetiapine) or chronic benzodiazepine use.
- •Subject has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.
- •Subject has history of abuse of alcohol or any drug substance within the previous 2 years.
- •Subject deemed to be a compliance risk or unlikely to keep clinic appointments.
- •Subject donated blood (≥ 500 mL) within the 12-week period before the initial study dose.
研究组 & 干预措施
JATENZO® twice daily
Experimental
Participants receive 237 mg JATENZO twice daily, with the potential to be titrated to a higher or lower dose depending on serum testosterone levels.
干预措施: Jatenzo (Drug)
结局指标
主要结局
CST Test
时间窗: 6 months and 12 months
To estimate the proportion of subjects with an abnormal post-stimulation cosyntropin stimulation test (CST) serum total cortisol level after approximately 6 and 12 months of treatment with JATENZO
次要结局
- Adrenal Insufficiency(12 months)
研究者
研究点 (24)
Loading locations...
相似试验
招募中
4 期
Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyPartial LipodystrophyNCT06484868Amryt Pharma12
已完成
4 期
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic ArthritisNCT03301883Hoffmann-La Roche62
进行中（未招募）
不适用
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationGeographic AtrophyNCT06161584Apellis Pharmaceuticals, Inc.300
已完成
4 期
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01563185Amgen12
已完成
4 期
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 YearsInfluenzaNCT00825162Seqirus1,992